The UK Clinical Trials Gateway uses
cookies
to ensure that we give you the best experience on our website. You may delete and block all cookies from this site at any time.
Our privacy policy has been updated. Please take the time to read it here.
By clicking "Accept" you are agreeing to the terms of the updated privacy and cookie policy.

UNDER DEVELOPMENT

This service will be redeveloped soon — your
feedback will help us to improve it.

This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.

Summary

Background and study aimsDry mouth is a common symptom of primary Sjogren’s syndrome (pSS) affecting speech, swallowing, oral health and quality of life. It is a distressing and persistent condition which can lead to long-lasting oral discomfort, dental infections, diminished quality of life, social isolation and loneliness. Unfortunately, current treatments for dry mouth are often unsatisfactory, only offering short-term relief, may be expensive and may result in side effects. A new electronic device has recently been developed to treat dry mouth. The device, acting as a “salivary pacemaker”, is taken home by the patient and works by being placed in the mouth as and when needed. It harmlessly releases electrical pulses to stimulate the nerves (electrostimulating) associated with saliva production. As the electrical pulse intensity is below the human sensitivity level, it cannot be felt by the patient. The aim of this study is to determine whether the device reduces dry mouth symptoms in patients with pSS. Who can participate?Patients aged 18 and over with pSS and dry mouthWhat does the study involve?Participants are randomly allocated to one of two groups. One group receives an active electrostimulating device that provides mechanical/tactile stimulation but also releases electrical pulses. The second group receives a sham device that does not release electricity but provides mechanical/tactile stimulation only. Both groups are asked to use the device for 12 months. Although there are some limitations to the duration and frequency of use (no more than once per hour and for a maximum duration of 10 minutes per hour), participants are largely free to use the device as and when needed. Neither doctors nor participants are aware of which devices are functional or sham to ensure that the study results cannot be influenced. Participants attend 5-6 hospital appointments over 12 months, where they are asked to complete questionnaires regarding their dry mouth symptoms, oral health, quality of life and use of health services. They are also asked to do two simple 5-minute tests which require them to spit their saliva.What are the possible benefits and risks of participating?Participants allocated to receive the active device will potentially benefit from a reduction in dry mouth symptoms, improved salivation and an improvement in their quality of life. Participants allocated to receive the sham device are also expected to benefit from some increase in salivation due to the tactile and mechanical stimulation of the sham device although the benefit is believed to be much lower than the benefit due to electrical stimulation. Therefore, although participants will be requested to stop taking pilocarpine (a salivary stimulant used in standard care by about 30% of patients) and will not be able to receive acupuncture for dry mouth (a treatment used by less than 1% of patients in standard care) for the duration of the study, it is anticipated that participants in both groups will benefit from using the device they are allocated to. All participants will also continue to be treated with standard of care treatment for dry mouth with the only exception of pilocarpine or acupuncture. These treatments include salivary substitutes (mouthwash, spray, gel), chewing sugar-free gums or sucking sugar-free pastilles or often simply frequent sips of water. Benefits to the participant include being closely monitored and supported by the research team in addition to the routine care received from the rheumatology or oral medicine teams. Participants will also receive an oral examination at each clinical assessment visit to check the device is not causing any mouth abnormalities, in particular relating to the placement of the electrodes. The results of this study may lead to a more clinically and cost effective way to treat the dry mouth symptoms of pSS in the future. The study team foresee minimal risks as the active device is CE marked with a well known safety profile, available freely to purchase and will be administered by suitably trained and qualified medical professionals. The sham device is a non-electrostimulatory version of the same device, identical in appearance, weight, taste and sensation. The device differs only in respect of the software, meaning the device does not possess any electrostimulation functions and hence raises no further safety concerns.Where is the study run from? 1. University College London Hospitals NHS Foundation Trust2. Sheffield Teaching Hospitals NHS Foundation Trust3. University Hospitals Birmingham Foundation Trust4. The Newcastle Upon Tyne Hospitals NHS Foundation Trust5. Great Western Hospital NHS Foundation Trust6. Royal Liverpool and Broadgreen University Hospitals NHS Trust 7. Leeds Teaching Hospitals NHS Foundation Trust8. Barts Health NHS TrustWhen is the study starting and how long is it expected to run for?April 2018 to April 2021Who is funding the study?Arthritis Research UKWho is the main contact?Ms Saila Waseems.waseem@leeds.ac.uk

Research Details

Dry mouth is a common manifestation of primary Sjogren’s syndrome (pSS) affecting speech, swallowing, oral health and quality of life. It is a distressing and persistent condition which can lead to long-lasting oral discomfort, dental infections, diminished quality of life, social isolation and loneliness. Unfortunately, current therapies of dry mouth are often unsatisfactory, only offering transient relief, may be expensive and may result in adverse effects. A novel intraoral electronic device has recently been developed to treat dry mouth. The device, acting as a “salivary pacemaker”, is taken home by the patient and works by being placed in the mouth as and when needed. It harmlessly releases electrical pulses to stimulate the nerves (electrostimulating) associated with salivary gland secretion. However, the electrical pulse intensity is below the human sensitivity level, therefore it cannot be felt by the patient.The aim of SALRISE is to determine whether the device reduces dry mouth symptoms in patients with pSS.

Phase

Sorry, this information is not available

Study Design

Randomised; Interventional; Design type: Treatment, Device

Study Type

Interventional

Intervention

This is a double­-blind randomised study of patients who have primary Sjogren's syndrome. The purpose of the study is specifically to ascertain the role of electro stimulation in the treatment of dry mouth for participants who have primary Sjogren's syndrome. A double-blind trial design has been selected as this minimises the possible introduction of bias.Patients will be identified for potential recruitment by investigators based in secondary care rheumatology or oral medicine clinics. They will be then approached by one of the clinicians of the study and/or a research nurse and provided with detailed information about the study. A total of 130 participants will be randomised in a 1:1 allocation to receive i) an active, salivary electrostimulating device that provides mechanical/tactile stimulation but also releases electrical pulses of specific patterns to stimulate the nerves associated with salivary gland secretion or ii) a sham device that does not release electricity but provides mechanical/tactile stimulation only. Both active and sham devices will be indistinguishable in appearance (using identical appearance, packaging, and labelling) and when in use (the electrical pulse intensity is below the human sensitivity level, therefore the electronic stimulus is completely asymptomatic). Neither clinical investigators nor participants will know which devices are active and which are sham. Participants will continue to be treated with standard of care therapy during the study with the exception of pilocarpine and acupuncture for the dry mouth symptoms of pSS as both these therapies have the potential to interfere with the outcome measures. Whilst the sham device will not release any electrostimulation it is expected that the mechanical/tactile stimulation may have a positive effect upon salivary production.The aim is to compare the dry mouth symptoms, safety and cost effectiveness of the device in both sets of participants 12 months after initiating use of the device. Participants will be asked to use the device up to 10 minutes/hour no more than once an hour, for a total of 52 weeks. They will be asked to attend follow-up visits at the secondary care site at weeks 4, 12, 26 and 52. At each follow-up visit they will be asked to complete questionnaires regarding their dry mouth symptoms, oral health, quality of life and use of health services. They will also be asked to do two simple 5-minute tests (a total of 10 minutes) which require them to spit their saliva into a test tube to measure their salivary production under different conditions i) when resting the mouth (unstimulated) and ii) whilst chewing on a block of paraffin wax (stimulated) and undergo a clinical oro-facial examination by a clinician trained to assess for abnormalities thought to be related to using the device. In addition, at week 39 they will be sent the same set of questionnaires referred to above to complete at home and return to the Clinical Trials Research Unit in a stamped addressed envelope. Study participants will also complete a daily diary detailing of the frequency of application of the device per day.Sample size calculationThis has been calculated with regard to the primary outcome. A total of 130 patients is required to have 90% power for detecting an effect size of 2.5 units for the change in XI score at 52 weeks post-randomisation assuming a between-patient standard deviation of 4 units, 2-sided 5% significance level and 15% loss to follow-upTimetable for the stages of the research:­- 24 months for recruitment of participants - 12 months of clinical trial ­- 7 months for data analysis

This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.

1. Patient has a cardiac pacemaker or other implanted electrostimulating device fitted, e.g. deep brain stimulation device, a cardiac defibrillator2. Patient has epileptic disorder, essential tremor, involuntary muscle movement disorder, e.g. Parkinson’s disease or trigeminal neuralgia3. Patient has evidence of chronic erosive/ulcerative disease or chronic keratotic disorders of the oral mucosa (e.g. lichen planus) or jaw osteonecrosis upon oral examination 4. Patient has suspected or confirmed malignant disease or pre-malignancy (dysplasia) of the oral mucosa 5. Patient has active malignancy (any organ other than the oral mucosa)6. Current pregnancy as confirmed by urine pregnancy test at Eligibility and Baseline Assessment visit7. Pilocarpine therapy during the 14 days prior to the Eligibility and Baseline Assessment visit8. Concomitant use of systemic sialogogue therapy (e.g. pilocarpine) throughout the study 9. Unstable dose over the 4 weeks prior to the Eligibility and Baseline Assessment visit of any medication or therapy known to have an effect upon saliva production (or 7 days in the case of antihistamines)10. Patient has received a rituximab infusion within the 6 months prior to the Eligibility and Baseline Assessment visit11. Patient has received acupuncture for the dry mouth symptoms of pSS within the 28 days prior to the Eligibility and Baseline Assessment visit12. Patient previously participated in LEONIDAS-1, already owns a SaliPen device, any of the earlier generations of the device or any other device with a similar electrostimulatory mode of action that acts upon the salivary glands.13. Expected non-compliance with treatment interventions or is considered unsuitable for trial participation at the discretion of the treating clinician/nurse

This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.

This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.

Scientific Title

SALivary electro-stimulation for the treatment of dry mouth in patients with Sjogren's syndrome: a multicentRe randomISEd sham-controlled double-blind study

EudraCT Number

Sorry, this information is not available

Funder(s)

Arthritis Research UK

Grant Codes: 21233

Other Study ID Numbers

38405

Sponsor(s)

University College London

Key Dates

Recruitment Start Date

13 Aug 2018

Recruitment End Date

01 Nov 2019

Trial Start Date

01 Apr 2018

Trial End Date

01 Apr 2021

Date added to source

02 Aug 2018

Date updated in source

02 Aug 2018

Subscribe to trial

Current status of trial is "Recruiting". If you subscribe now, we will notify you by email when the status changes to "Completed".

Email address

Send this trial to a friend

Thank you for helping us grow and improving medical research!

If you know someone who would be interested in this clinical trials, enter their email address.You are sending them the link for the trial open on this page. you can send the link to another person once this link has been sent.